ANIP
ANI Pharmaceuticals Inc
72.20$
-1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 36.5% | 40.6% | 35.8% | 41.8% | 42.5% | 42.1% | 37.1% | 35.3% | 50.9% | 3.8% | 48.2% | 37.6% | 34.8% | |
| 63.5% | 59.4% | 64.2% | 58.2% | 57.5% | 57.9% | 62.9% | 64.7% | 49.1% | 96.2% | 51.8% | 62.4% | 65.2% | |
| 8.4% | 7.5% | 7.6% | 5.3% | 6.8% | 8.7% | 5.4% | 7.8% | 5.4% | 5.0% | 4.5% | 5.5% | 5.1% | |
| 31.9% | 33.8% | 34.9% | 38.3% | 53.3% | 36.6% | 38.8% | 38.7% | 33.6% | 31.0% | 31.0% | 34.5% | 32.6% | |
| 49.9% | 54.3% | 49.5% | 54.5% | 71.3% | 60.2% | 49.7% | 58.1% | 39.0% | 76.7% | 35.5% | 47.1% | 49.9% | |
| 13.6% | 5.1% | 14.8% | 3.7% | -13.8% | -2.3% | 13.3% | 6.6% | 10.0% | 19.5% | 16.3% | 15.2% | 15.3% | |
| 4.9% | 4.4% | 3.3% | 3.4% | 1.6% | 3.2% | 4.1% | 3.9% | 2.1% | 9.2% | 1.6% | 1.4% | 3.6% | |
| 8.7% | 0.7% | 18.4% | -1.7% | -21.2% | -7.2% | 10.1% | 5.0% | 14.8% | 12.7% | 16.9% | 13.9% | 14.6% | |
| 1.2% | -0.2% | 5.2% | – | -4.9% | -1.8% | 2.2% | 0.9% | 3.2% | 1.6% | 4.5% | 4.7% | 3.5% | |
| 7.5% | 0.9% | 13.2% | -1.7% | -16.3% | -5.4% | 8.0% | 4.0% | 10.6% | 11.1% | 12.4% | 9.3% | 10.8% | |
| 25.1% | 16.6% | 32.5% | 12.4% | -9.0% | 7.8% | 24.5% | 18.6% | 26.8% | 31.1% | 24.2% | 22.7% | 26.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.